LIPOSYN II 20% EMULSION

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

SAFFLOWER OIL; SOYBEAN OIL; EGG PHOSPHOLIPIDS

Tilgængelig fra:

HOSPIRA HEALTHCARE ULC

ATC-kode:

B05BA02

INN (International Name):

FAT EMULSIONS

Dosering:

10%; 10%; 1.2%

Lægemiddelform:

EMULSION

Sammensætning:

SAFFLOWER OIL 10%; SOYBEAN OIL 10%; EGG PHOSPHOLIPIDS 1.2%

Indgivelsesvej:

INTRAVENOUS

Enheder i pakken:

500ML

Recept type:

Ethical

Terapeutisk område:

CALORIC AGENTS

Produkt oversigt:

Active ingredient group (AIG) number: 0318894001; AHFS:

Autorisation status:

CANCELLED POST MARKET

Autorisation dato:

2014-08-01

Produktets egenskaber

PRODUCT MONOGRAPH
LIPOSYN® II 10% Injection
LIPOSYN® II 20% Injection
Intravenous Fat Emulsion 10% and 20%
Intravenous Nutrient Supplement
Hospira Healthcare Corporation
DATE OF PREPARATION:
5400 Côte-de-Liesse
January 13, 2005
Town of Mount Royal (QC) CANADA
H4P 1A5
Control # 096408
- 2 -
NAMES OF DRUG
LIPOSYN® II 10% Injection
LIPOSYN® II 20% Injection
Intravenous Fat Emulsion 10% and 20%
THERAPEUTIC CLASSIFICATION
Intravenous Nutrient Supplement
ACTION
LIPOSYN® II Injection (Intravenous Fat Emulsion 10% and 20%) provides
the patient requiring
parenteral nutrition with a source of calories and the essential fatty
acids normally obtained from
a nutritionally complete oral diet. The supplemental polyunsaturated
fat prevents biochemical
changes of essential fatty acid deficiency (EFAD) and prevents and
reverses EFAD clinical
manifestations (scaliness of skin, growth retardation, poor wound
healing, sparse hair growth). The
infused fat particles are cleared from the bloodstream in a manner
thought to be similar to the
clearing of chylomicrons.
INDICATIONS AND CLINICAL USE
LIPOSYN® II Injection (Intravenous Fat Emulsion 10% and 20%) is
indicated as a source of
calories for patients requiring parenteral nutrition. This includes
pre- and post-operative nutritional
disorders and nutritive disorders resulting from decreased or
inhibited intestinal absorption, as with
tumours of the digestive tract, or in ulcerative colitis and terminal
ileitis.
LIPOSYN® II Injection is also indicated in burn cases, where nitrogen
loss can be excessive, in
prolonged states of unconsciousness if tube feeding is inadvisable and
in cachexia due to serious
diseases other than of the alimentary tract.
Where such nutrition is required for extended periods of time (more
than five days), LIPOSYN® II
Injection is also indicated as a source of essential fatty acids to
prevent or reverse biochemical
changes in fatty acid composition of plasma lipids (elevated
triene/tetraene ratio) and the clinical
manifestations of EFAD.
CONTRAINDICATIONS